A study is funded by the tobacco industry to examine the association between smoking and lung cancer. They design a study with a prospective cohort of 1,000 smokers between the ages of 20-30. The length of the study is five years. After the study period ends, they conclude that there is no relationship between smoking and lung cancer. Which of the following study features is the most likely reason for the failure of the study to note an association between tobacco use and cancer?
Q2
A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?
Q3
A 25-year-old man with a genetic disorder presents for genetic counseling because he is concerned about the risk that any children he has will have the same disease as himself. Specifically, since childhood he has had difficulty breathing requiring bronchodilators, inhaled corticosteroids, and chest physiotherapy. He has also had diarrhea and malabsorption requiring enzyme replacement therapy. If his wife comes from a population where 1 in 10,000 people are affected by this same disorder, which of the following best represents the likelihood a child would be affected as well?
Q4
You are reviewing the protocol for a retrospective case-control study investigating risk factors for mesothelioma among retired factory workers. 100 cases of mesothelioma and 100 age and sex matched controls are to be recruited and interviewed about their exposure to industrial grade fiberglass by blinded interviewers. The investigators' primary hypothesis is that cases of mesothelioma will be more likely to have been exposed to industrial grade fiberglass. The design of this study is most concerning for which type of bias?
Q5
A recent study attempted to analyze whether increased "patient satisfaction" driven healthcare resulted in increased hospitalization. In this hospital, several of the wards adopted new aspects of "patient satisfaction" driven healthcare, whereas the remainder of the hospital continued to use existing protocols. Baseline population characteristics and demographics were collected at the start of the study. At the end of the following year, hospital use was assessed and compared between the two groups. Which of the following best describes this type of study?
Q6
You are reading through a recent article that reports significant decreases in all-cause mortality for patients with malignant melanoma following treatment with a novel biological infusion. Which of the following choices refers to the probability that a study will find a statistically significant difference when one truly does exist?
Q7
A group of environmental health scientists recently performed a nationwide cross-sectional study that investigated the risk of head and neck cancers in patients with a history of cigar and pipe smoking. In collaboration with three teams of epidemiologists that have each conducted similar cross-sectional studies in their respective countries, they have agreed to contribute their data to an international pooled analysis of the relationship between non-cigarette tobacco consumption and prevalence of head and neck cancers. Which of the following statements regarding the pooled analysis in comparison to the individual studies is true?
Q8
A healthy 29-year-old nulligravid woman comes to the physician for genetic counseling prior to conception. Her brother has a disease that has resulted in infertility, a right-sided heart, and frequent sinus and ear infections. No other family members are affected. The intended father has no history of this disease. The population prevalence of this disease is 1 in 40,000. Which of the following best represents the chance that this patient’s offspring will develop her brother's disease?
Q9
You are currently employed as a clinical researcher working on clinical trials of a new drug to be used for the treatment of Parkinson's disease. Currently, you have already determined the safe clinical dose of the drug in a healthy patient. You are in the phase of drug development where the drug is studied in patients with the target disease to determine its efficacy. Which of the following phases is this new drug currently in?
Q10
You are interested in studying the etiology of heart failure reduced ejection fraction (HFrEF) and attempt to construct an appropriate design study. Specifically, you wish to look for potential causality between dietary glucose consumption and HFrEF. Which of the following study designs would allow you to assess for and determine this causality?
Nested case-control studies US Medical PG Practice Questions and MCQs
Question 1: A study is funded by the tobacco industry to examine the association between smoking and lung cancer. They design a study with a prospective cohort of 1,000 smokers between the ages of 20-30. The length of the study is five years. After the study period ends, they conclude that there is no relationship between smoking and lung cancer. Which of the following study features is the most likely reason for the failure of the study to note an association between tobacco use and cancer?
A. Late-look bias
B. Latency period (Correct Answer)
C. Confounding
D. Effect modification
E. Pygmalion effect
Explanation: ***Latency period***
- **Lung cancer** typically has a **long latency period**, often **20-30+ years**, between initial exposure to tobacco carcinogens and the development of clinically detectable disease.
- A **five-year study duration** in young smokers (ages 20-30) is **far too short** to observe the development of lung cancer, which explains the false negative finding.
- This represents a **fundamental flaw in study design** rather than a bias—the biological timeline of disease development was not adequately considered.
*Late-look bias*
- **Late-look bias** occurs when a study enrolls participants who have already survived the early high-risk period of a disease, leading to **underestimation of true mortality or incidence**.
- Also called **survival bias**, it involves studying a population that has already been "selected" by survival.
- This is not applicable here, as the study simply ended before sufficient time elapsed for disease to develop.
*Confounding*
- **Confounding** occurs when a third variable is associated with both the exposure and outcome, distorting the apparent relationship between them.
- While confounding can affect study results, it would not completely eliminate the detection of a strong, well-established association like smoking and lung cancer in a properly conducted prospective cohort study.
- The issue here is temporal (insufficient follow-up time), not the presence of an unmeasured confounder.
*Effect modification*
- **Effect modification** (also called interaction) occurs when the magnitude of an association between exposure and outcome differs across levels of a third variable.
- This represents a **true biological phenomenon**, not a study design flaw or bias.
- It would not explain the complete failure to detect any association.
*Pygmalion effect*
- The **Pygmalion effect** (observer-expectancy effect) refers to a psychological phenomenon where higher expectations lead to improved performance in the observed subjects.
- This concept is relevant to **behavioral and educational research**, not to objective epidemiological studies of disease incidence.
- It has no relevance to the biological relationship between carcinogen exposure and cancer development.
Question 2: A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?
A. Level 1
B. Level 3 (Correct Answer)
C. Level 5
D. Level 4
E. Level 2
Explanation: ***Level 3***
- A **non-randomized controlled trial** like the one described, where patient assignment to treatment groups is based on specific characteristics (risk of toxicity), falls into Level 3 evidence.
- This level typically includes **non-randomized controlled trials** and **well-designed cohort studies** with comparison groups, which are prone to selection bias and confounding.
- The study compares two treatments but lacks randomization, making it Level 3 evidence.
*Level 1*
- Level 1 evidence is the **highest level of evidence**, derived from **systematic reviews and meta-analyses** of multiple well-designed randomized controlled trials or large, high-quality randomized controlled trials.
- The described study is explicitly stated as non-randomized, ruling out Level 1.
*Level 2*
- Level 2 evidence involves at least one **well-designed randomized controlled trial** (RCT) or **systematic reviews** of randomized trials.
- The current study is *non-randomized*, which means it cannot be classified as Level 2 evidence, as randomization is a key criterion for this level.
*Level 4*
- Level 4 evidence includes **case series**, **case-control studies**, and **poorly designed cohort or case-control studies**.
- While the study is non-randomized, it is a controlled comparative trial rather than a case series or retrospective case-control study, placing it at Level 3.
*Level 5*
- Level 5 evidence is the **lowest level of evidence**, typically consisting of **expert opinion** without explicit critical appraisal, or based on physiology, bench research, or animal studies.
- While the drug was initially tested in animal studies, the current human comparative study offers a higher level of evidence than expert opinion or preclinical data.
Question 3: A 25-year-old man with a genetic disorder presents for genetic counseling because he is concerned about the risk that any children he has will have the same disease as himself. Specifically, since childhood he has had difficulty breathing requiring bronchodilators, inhaled corticosteroids, and chest physiotherapy. He has also had diarrhea and malabsorption requiring enzyme replacement therapy. If his wife comes from a population where 1 in 10,000 people are affected by this same disorder, which of the following best represents the likelihood a child would be affected as well?
A. 0.01%
B. 2%
C. 0.5%
D. 1% (Correct Answer)
E. 50%
Explanation: ***Correct Option: 1%***
- The patient's symptoms (difficulty breathing requiring bronchodilators, inhaled corticosteroids, and chest physiotherapy; diarrhea and malabsorption requiring enzyme replacement therapy) are classic for **cystic fibrosis (CF)**, an **autosomal recessive disorder**.
- For an autosomal recessive disorder with a prevalence of 1 in 10,000 in the general population, **q² = 1/10,000**, so **q = 1/100 = 0.01**. The carrier frequency **(2pq)** is approximately **2q = 2 × (1/100) = 1/50 = 0.02**.
- The affected man is **homozygous recessive (aa)** and will always pass on the recessive allele. His wife has a **1/50 chance of being a carrier (Aa)**. If she is a carrier, she has a **1/2 chance of passing on the recessive allele**.
- Therefore, the probability of an affected child = **(Probability wife is a carrier) × (Probability wife passes recessive allele) = 1/50 × 1/2 = 1/100 = 1%**.
*Incorrect Option: 0.01%*
- This percentage is too low and does not correctly account for the carrier frequency in the population and the probability of transmission from a carrier mother.
*Incorrect Option: 2%*
- This represents approximately the carrier frequency (1/50 ≈ 2%), but does not account for the additional 1/2 probability that a carrier mother would pass on the recessive allele.
*Incorrect Option: 0.5%*
- This value would be correct if the carrier frequency were 1/100 instead of 1/50, which does not match the given population prevalence.
*Incorrect Option: 50%*
- **50%** would be the risk if both parents were carriers of an autosomal recessive disorder (1/4 chance = 25% for affected, but if we know one parent passes the allele, conditional probability changes). More accurately, 50% would apply if the disorder were **autosomal dominant** with one affected parent, which is not the case here.
Question 4: You are reviewing the protocol for a retrospective case-control study investigating risk factors for mesothelioma among retired factory workers. 100 cases of mesothelioma and 100 age and sex matched controls are to be recruited and interviewed about their exposure to industrial grade fiberglass by blinded interviewers. The investigators' primary hypothesis is that cases of mesothelioma will be more likely to have been exposed to industrial grade fiberglass. The design of this study is most concerning for which type of bias?
A. This study design is free of potential bias
B. Observer bias
C. Interviewer bias
D. Lead-time bias
E. Recall bias (Correct Answer)
Explanation: ***Recall bias***
- In a retrospective **case-control study**, individuals with mesothelioma (cases) may be more likely to **recall and report past exposures** to industrial-grade fiberglass than controls, due to their diagnosis and their search for an explanation for their illness.
- This differential recall of past exposures between cases and controls can distort the true association between the exposure and the disease, leading to a biased estimate of risk.
- Cases do not necessarily remember more accurately; rather, they may over-report or selectively remember exposures they believe might be causally related to their disease.
*This study design is free of potential bias*
- This statement is incorrect because **no study design is completely free of potential biases**, especially in observational studies like this case-control design.
- While efforts like blinded interviewers are made, inherent limitations of retrospective data collection can introduce other forms of bias.
*Observer bias*
- **Observer bias** typically refers to situations where the researcher's expectations or beliefs influence the recording of data, but the study description states **blinded interviewers** are used, which aims to mitigate this type of bias.
- This bias is less likely here due to the blinding, and the primary concern relates to the participants' memory of past events.
*Interviewer bias*
- **Interviewer bias** can occur when the interviewer's behavior or questioning influences the participant's responses.
- However, the protocol mitigates this by using **blinded interviewers**, meaning they are unaware of the case/control status of the participants, reducing the risk of differential questioning.
*Lead-time bias*
- **Lead-time bias** is primarily a concern in screening studies where early detection of a disease might artificially prolong the survival time without actually changing the course of the disease.
- This study is investigating risk factors for mesothelioma, not evaluating the effectiveness of a screening program, rendering lead-time bias irrelevant to this design.
Question 5: A recent study attempted to analyze whether increased "patient satisfaction" driven healthcare resulted in increased hospitalization. In this hospital, several of the wards adopted new aspects of "patient satisfaction" driven healthcare, whereas the remainder of the hospital continued to use existing protocols. Baseline population characteristics and demographics were collected at the start of the study. At the end of the following year, hospital use was assessed and compared between the two groups. Which of the following best describes this type of study?
A. Prospective cohort (Correct Answer)
B. Cross-sectional study
C. Retrospective case-control
D. Prospective case-control
E. Retrospective cohort
Explanation: ***Prospective cohort***
- This study design involves following a group of **exposed individuals (patient satisfaction-driven healthcare)** and a group of **unexposed individuals (existing protocols)** forward in time to observe the development of an outcome (**hospitalization**).
- The exposure status is determined at the **start of the study (baseline)**, and outcomes are measured prospectively over a period, which aligns with observing hospital use over the following year.
*Cross-sectional study*
- A **cross-sectional study** assesses both exposure and outcome simultaneously at a single point in time, providing a snapshot.
- This study design involves follow-up over a year, making it unsuitable for a cross-sectional classification.
*Retrospective case-control*
- A **retrospective case-control study** begins with identifying individuals based on their outcome status (cases with the outcome and controls without the outcome) and then looks back in time to determine past exposures.
- This study starts by defining exposure groups and then follows them to observe future outcomes, which is the opposite of a case-control design.
*Prospective case-control*
- A **prospective case-control study** is a less common and often refers to a nested case-control study within a cohort, where cases and controls are selected from a larger cohort that has been followed prospectively.
- The described study directly follows entire exposed and unexposed groups without specifically selecting cases and controls from a pre-defined cohort.
*Retrospective cohort*
- A **retrospective cohort study** defines cohorts based on past exposures using existing data and then looks back in time to determine outcomes that have already occurred.
- The study explicitly states that hospital use was assessed at the "end of the following year," indicating a forward-looking collection of outcome data, not a retrospective assessment of already recorded outcomes.
Question 6: You are reading through a recent article that reports significant decreases in all-cause mortality for patients with malignant melanoma following treatment with a novel biological infusion. Which of the following choices refers to the probability that a study will find a statistically significant difference when one truly does exist?
A. Type II error
B. Type I error
C. Confidence interval
D. p-value
E. Power (Correct Answer)
Explanation: ***Power***
- **Power** is the probability that a study will correctly reject the null hypothesis when it is, in fact, false (i.e., will find a statistically significant difference when one truly exists).
- A study with high power minimizes the risk of a **Type II error** (failing to detect a real effect).
*Type II error*
- A **Type II error** (or **beta error**) occurs when a study fails to reject a false null hypothesis, meaning it concludes there is no significant difference when one actually exists.
- This is the **opposite** of what the question describes, which asks for the probability of *finding* a difference.
*Type I error*
- A **Type I error** (or **alpha error**) occurs when a study incorrectly rejects a true null hypothesis, concluding there is a significant difference when one does not actually exist.
- This relates to the **p-value** and the level of statistical significance (e.g., p < 0.05).
*Confidence interval*
- A **confidence interval** provides a range of values within which the true population parameter is likely to lie with a certain degree of confidence (e.g., 95%).
- It does not directly represent the probability of finding a statistically significant difference when one truly exists.
*p-value*
- The **p-value** is the probability of observing data as extreme as, or more extreme than, that obtained in the study, assuming the null hypothesis is true.
- It is used to determine statistical significance, but it is not the probability of detecting a true effect.
Question 7: A group of environmental health scientists recently performed a nationwide cross-sectional study that investigated the risk of head and neck cancers in patients with a history of cigar and pipe smoking. In collaboration with three teams of epidemiologists that have each conducted similar cross-sectional studies in their respective countries, they have agreed to contribute their data to an international pooled analysis of the relationship between non-cigarette tobacco consumption and prevalence of head and neck cancers. Which of the following statements regarding the pooled analysis in comparison to the individual studies is true?
A. The results are less precise.
B. It overcomes limitations in the quality of individual studies.
C. It is able to provide evidence of causality.
D. The level of clinical evidence is lower.
E. The likelihood of type II errors is decreased. (Correct Answer)
Explanation: ***The likelihood of type II errors is decreased.***
- A pooled analysis or **meta-analysis** combines data from multiple studies, significantly increasing the **overall sample size**.
- A larger sample size enhances the statistical power, making it less likely to miss a real effect and thus reducing the probability of **Type II errors** (false negatives).
*The results are less precise.*
- Combining data from multiple studies in a **pooled analysis** generally leads to **more precise estimates** due to the larger sample size and increased statistical power.
- Increased precision is reflected in narrower confidence intervals, offering a more reliable estimate of the effect.
*It overcomes limitations in the quality of individual studies.*
- A pooled analysis **does not inherently overcome limitations** in the design, methodology, or quality of the individual studies included.
- If the original studies have significant biases or flaws, these limitations can be propagated or even amplified in the pooled results.
*It is able to provide evidence of causality.*
- Pooled analyses of **cross-sectional studies**, like the ones described, can identify **associations** but cannot establish **causality**.
- Cross-sectional studies measure exposure and outcome simultaneously, making it impossible to determine the temporal sequence necessary to infer cause and effect.
*The level of clinical evidence is lower.*
- Combining multiple studies, especially well-conducted ones, in a pooled analysis or **meta-analysis** generally **increases the level of clinical evidence**, placing it higher than individual observational studies.
- This is because a pooled analysis offers a more robust and comprehensive view of the existing evidence.
Question 8: A healthy 29-year-old nulligravid woman comes to the physician for genetic counseling prior to conception. Her brother has a disease that has resulted in infertility, a right-sided heart, and frequent sinus and ear infections. No other family members are affected. The intended father has no history of this disease. The population prevalence of this disease is 1 in 40,000. Which of the following best represents the chance that this patient’s offspring will develop her brother's disease?
A. 25%
B. 66%
C. 0.2% (Correct Answer)
D. 0.7%
E. 1%
Explanation: ***0.2%***
- The brother's symptoms (infertility, right-sided heart, frequent infections) are characteristic of **Kartagener syndrome**, a form of **primary ciliary dyskinesia (PCD)**, which has an **autosomal recessive** inheritance pattern.
- Since the patient's parents are obligate heterozygotes (carriers), the patient has a 2/3 chance of being a carrier. Given the population prevalence of 1/40,000 for an autosomal recessive disease, the carrier frequency (2pq) is approximately **2 x sqrt(1/40,000) = 2 x 1/200 = 1/100**. The chance of her child inheriting the disease is (2/3 chance of patient being carrier) x (1/100 chance of partner being carrier) x (1/4 chance of affected offspring) = 2/1200 ≈ **0.00166 or 0.166%**, which is closest to 0.2%.
*25%*
- This would be the risk if both parents were known carriers, and it represents the chance of an affected offspring from two heterozygotes.
- In this scenario, the woman's partner's carrier status is unknown and based on population prevalence, making the overall risk much lower.
*66%*
- This is the probability that the patient (the healthy sister of an affected individual with an autosomal recessive disease) is a **carrier**.
- This value alone does not account for the partner's carrier status or the final Mendelian inheritance probability (1/4) for an affected child.
*0.7%*
- This percentage is too high; it might result from incorrect calculation of the population carrier frequency or misapplication of probabilities.
- The correct carrier frequency for the partner is 1/100, which is significantly lower than what would lead to a 0.7% final risk.
*1%*
- This value is also too high and likely results from a miscalculation of either the carrier frequency or the overall probability.
- A 1% chance would suggest a much higher population carrier frequency or a different inheritance scenario.
Question 9: You are currently employed as a clinical researcher working on clinical trials of a new drug to be used for the treatment of Parkinson's disease. Currently, you have already determined the safe clinical dose of the drug in a healthy patient. You are in the phase of drug development where the drug is studied in patients with the target disease to determine its efficacy. Which of the following phases is this new drug currently in?
A. Phase 4
B. Phase 1
C. Phase 2 (Correct Answer)
D. Phase 0
E. Phase 3
Explanation: ***Phase 2***
- **Phase 2 trials** involve studying the drug in patients with the target disease to assess its **efficacy** and further evaluate safety, typically involving a few hundred patients.
- The question describes a stage after safe dosing in healthy patients (Phase 1) and before large-scale efficacy confirmation (Phase 3), focusing on efficacy in the target population.
*Phase 4*
- **Phase 4 trials** occur **after a drug has been approved** and marketed, monitoring long-term effects, optimal use, and rare side effects in a diverse patient population.
- This phase is conducted post-market approval, whereas the question describes a drug still in development prior to approval.
*Phase 1*
- **Phase 1 trials** primarily focus on determining the **safety and dosage** of a new drug in a **small group of healthy volunteers** (or sometimes patients with advanced disease if the drug is highly toxic).
- The question states that the safe clinical dose in a healthy patient has already been determined, indicating that Phase 1 has been completed.
*Phase 0*
- **Phase 0 trials** are exploratory, very early-stage studies designed to confirm that the drug reaches the target and acts as intended, typically involving a very small number of doses and participants.
- These trials are conducted much earlier in the development process, preceding the determination of safe clinical doses and large-scale efficacy studies.
*Phase 3*
- **Phase 3 trials** are large-scale studies involving hundreds to thousands of patients to confirm **efficacy**, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug to be used safely.
- While Phase 3 does assess efficacy, it follows Phase 2 and is typically conducted on a much larger scale before submitting for regulatory approval.
Question 10: You are interested in studying the etiology of heart failure reduced ejection fraction (HFrEF) and attempt to construct an appropriate design study. Specifically, you wish to look for potential causality between dietary glucose consumption and HFrEF. Which of the following study designs would allow you to assess for and determine this causality?
A. Cross-sectional study
B. Case series
C. Cohort study (Correct Answer)
D. Case-control study
E. Randomized controlled trial
Explanation: ***Cohort study***
- A **cohort study** observes a group of individuals over time to identify risk factors and outcomes, allowing for the assessment of **temporal relationships** between exposure (dietary glucose) and outcome (HFrEF).
- This design is suitable for establishing a potential **causal link** as it tracks participants from exposure to outcome, enabling the calculation of incidence rates and relative risks.
*Cross-sectional study*
- A **cross-sectional study** measures exposure and outcome simultaneously at a single point in time, making it impossible to determine the **temporal sequence** of events.
- This design can only identify **associations** or correlations, not causation, as it cannot establish whether high glucose consumption preceded HFrEF.
*Case series*
- A **case series** describes characteristics of a group of patients with a particular disease or exposure, often to highlight unusual clinical features, but it lacks a **comparison group**.
- It cannot assess causality because it does not provide information on the frequency of exposure in healthy individuals or the incidence of the disease in unexposed individuals.
*Case-control study*
- A **case-control study** compares individuals with the outcome (cases) to those without the outcome (controls) to determine past exposures, which makes it prone to **recall bias**.
- While it can suggest associations, it cannot definitively establish a temporal relationship or causation as the outcome is already known when exposure is assessed.
*Randomized controlled trial*
- A **randomized controlled trial (RCT)** is the gold standard for establishing causation by randomly assigning participants to an intervention or control group, but it may not be ethical or feasible for studying long-term dietary exposures and chronic diseases like HFrEF due to the long follow-up period and complexity of diet.
- While ideal for causality, directly controlling and randomizing dietary glucose intake over decades to observe HFrEF development might be practically challenging or unethical.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
